JP6482533B2 - クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 - Google Patents
クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 Download PDFInfo
- Publication number
- JP6482533B2 JP6482533B2 JP2016514143A JP2016514143A JP6482533B2 JP 6482533 B2 JP6482533 B2 JP 6482533B2 JP 2016514143 A JP2016514143 A JP 2016514143A JP 2016514143 A JP2016514143 A JP 2016514143A JP 6482533 B2 JP6482533 B2 JP 6482533B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- subject
- variants
- tnfsf15
- locus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000011231 Crohn disease Diseases 0.000 title claims description 52
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 title claims description 39
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 title claims description 35
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 title claims description 33
- 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 title claims 7
- 238000000034 method Methods 0.000 claims description 72
- 238000003556 assay Methods 0.000 claims description 19
- 238000003205 genotyping method Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 3
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 claims 7
- 102100026238 Lymphotoxin-alpha Human genes 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 101150096316 5 gene Proteins 0.000 claims 4
- 230000006978 adaptation Effects 0.000 claims 2
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 27
- 206010016654 Fibrosis Diseases 0.000 description 25
- 230000004761 fibrosis Effects 0.000 description 25
- 230000008901 benefit Effects 0.000 description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 102000054766 genetic haplotypes Human genes 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 208000031481 Pathologic Constriction Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 206010028116 Mucosal inflammation Diseases 0.000 description 3
- 201000010927 Mucositis Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000000513 principal component analysis Methods 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 238000011477 surgical intervention Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 206010072877 Intestinal fibrosis Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000002966 stenotic effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361824932P | 2013-05-17 | 2013-05-17 | |
| US61/824,932 | 2013-05-17 | ||
| PCT/US2014/038468 WO2014186750A2 (en) | 2013-05-17 | 2014-05-16 | Variants of tnfsf15 and dcr3 associated with crohn's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018124311A Division JP2018148931A (ja) | 2013-05-17 | 2018-06-29 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016526875A JP2016526875A (ja) | 2016-09-08 |
| JP2016526875A5 JP2016526875A5 (enExample) | 2017-06-15 |
| JP6482533B2 true JP6482533B2 (ja) | 2019-03-13 |
Family
ID=51899024
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016514143A Active JP6482533B2 (ja) | 2013-05-17 | 2014-05-16 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
| JP2018124311A Withdrawn JP2018148931A (ja) | 2013-05-17 | 2018-06-29 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
| JP2020096798A Withdrawn JP2020127437A (ja) | 2013-05-17 | 2020-06-03 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
| JP2022093628A Withdrawn JP2022111329A (ja) | 2013-05-17 | 2022-06-09 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
| JP2024213907A Pending JP2025023316A (ja) | 2013-05-17 | 2024-12-06 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018124311A Withdrawn JP2018148931A (ja) | 2013-05-17 | 2018-06-29 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
| JP2020096798A Withdrawn JP2020127437A (ja) | 2013-05-17 | 2020-06-03 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
| JP2022093628A Withdrawn JP2022111329A (ja) | 2013-05-17 | 2022-06-09 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
| JP2024213907A Pending JP2025023316A (ja) | 2013-05-17 | 2024-12-06 | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20160090629A1 (enExample) |
| EP (3) | EP3498867B1 (enExample) |
| JP (5) | JP6482533B2 (enExample) |
| KR (4) | KR102295125B1 (enExample) |
| CN (1) | CN105358713B (enExample) |
| ES (1) | ES2894963T3 (enExample) |
| WO (1) | WO2014186750A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| BR112014007426B1 (pt) | 2011-09-30 | 2023-01-03 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpos contra tl1a e seus usos |
| EP3639841B1 (en) | 2013-03-27 | 2023-09-06 | Cedars-Sinai Medical Center | Treating fibrosis by inhibiting tl1a |
| KR102295125B1 (ko) | 2013-05-17 | 2021-08-31 | 세다르스-신나이 메디칼 센터 | 크론병과 연관된 tnfsf15와 dcr3의 변이체 |
| EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| EP3337509A4 (en) | 2015-08-21 | 2019-01-02 | The Children's Hospital of Philadelphia | Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| JP7082945B2 (ja) | 2016-03-17 | 2022-06-09 | シーダーズ―シナイ メディカル センター | Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法 |
| KR102481305B1 (ko) * | 2016-05-20 | 2022-12-26 | 세다르스-신나이 메디칼 센터 | 유전자에 기반한 염증성 장 질환의 진단 |
| CA3111819A1 (en) * | 2018-09-07 | 2020-03-12 | The Children's Hospital Of Philadelphia | Compositions and methods for the diagnosis and treatment of lymphatic system disorders |
| WO2020232125A1 (en) | 2019-05-14 | 2020-11-19 | Prometheus Biosciences, Inc. | Tl1a patient selection methods, systems, and devices |
| AU2020346580A1 (en) * | 2019-09-13 | 2022-03-31 | Kyowa Kirin Co., Ltd. | DcR3 variant |
| WO2022103961A1 (en) * | 2020-11-13 | 2022-05-19 | Prometheus Biosciences, Inc. | Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a |
| WO2025038473A1 (en) | 2023-08-11 | 2025-02-20 | Paragon Therapeutics, Inc. | Tl1a binding antibodies and methods of use |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US20090186034A1 (en) * | 2006-12-19 | 2009-07-23 | Genetech, Inc. | Gene expression markers for inflammatory bowel disease |
| WO2008106451A2 (en) * | 2007-02-26 | 2008-09-04 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
| WO2009052512A2 (en) | 2007-10-19 | 2009-04-23 | Cedars-Sinai Medical Center | Methods of using genetic variants to diagnose and predict inflammatory bowel disease |
| AU2009215441B2 (en) * | 2008-02-19 | 2015-07-02 | The Children's Hospital Of Philadelphia | Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same |
| WO2010118210A1 (en) * | 2009-04-08 | 2010-10-14 | Cedars-Sinai Medical Center | Methods of predicting complication and surgery in crohn's disease |
| CA2758531C (en) * | 2009-04-14 | 2018-11-13 | Derren Barken | Inflammatory bowel disease prognostics |
| AU2011317149B2 (en) | 2010-10-18 | 2015-05-07 | Société des Produits Nestlé S.A. | Methods for determining anti-drug antibody isotypes |
| ES2530175T3 (es) | 2011-02-17 | 2015-02-26 | Nestec S.A. | Ensayos para la detección de autoanticuerpos contra fármacos anti-TNF |
| WO2012161856A1 (en) | 2011-05-20 | 2012-11-29 | Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof |
| US20140170157A1 (en) | 2011-06-15 | 2014-06-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of selecting therapeutic indications |
| EP2565277A1 (en) | 2011-09-05 | 2013-03-06 | Progenika Biopharma, S.A. | Method for predicting radiographic severity in ankylosing spondylitis |
| SG11201401536QA (en) | 2011-10-21 | 2014-05-29 | Nestec Sa | Methods for improving inflammatory bowel disease diagnosis |
| KR102295125B1 (ko) | 2013-05-17 | 2021-08-31 | 세다르스-신나이 메디칼 센터 | 크론병과 연관된 tnfsf15와 dcr3의 변이체 |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| JP7082945B2 (ja) | 2016-03-17 | 2022-06-09 | シーダーズ―シナイ メディカル センター | Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法 |
-
2014
- 2014-05-16 KR KR1020157034355A patent/KR102295125B1/ko active Active
- 2014-05-16 US US14/890,712 patent/US20160090629A1/en not_active Abandoned
- 2014-05-16 KR KR1020237020524A patent/KR20230093538A/ko not_active Ceased
- 2014-05-16 CN CN201480038133.6A patent/CN105358713B/zh active Active
- 2014-05-16 EP EP18201967.9A patent/EP3498867B1/en active Active
- 2014-05-16 KR KR1020257028341A patent/KR20250130857A/ko active Pending
- 2014-05-16 WO PCT/US2014/038468 patent/WO2014186750A2/en not_active Ceased
- 2014-05-16 ES ES18201967T patent/ES2894963T3/es active Active
- 2014-05-16 EP EP21193676.0A patent/EP3988673A3/en active Pending
- 2014-05-16 JP JP2016514143A patent/JP6482533B2/ja active Active
- 2014-05-16 EP EP14797214.5A patent/EP2997165A4/en not_active Withdrawn
- 2014-05-16 KR KR1020217026836A patent/KR20210107176A/ko not_active Ceased
-
2018
- 2018-04-05 US US15/946,632 patent/US20180230543A1/en not_active Abandoned
- 2018-06-29 JP JP2018124311A patent/JP2018148931A/ja not_active Withdrawn
-
2020
- 2020-06-03 JP JP2020096798A patent/JP2020127437A/ja not_active Withdrawn
-
2021
- 2021-08-02 US US17/392,098 patent/US12281359B2/en active Active
-
2022
- 2022-06-09 JP JP2022093628A patent/JP2022111329A/ja not_active Withdrawn
-
2024
- 2024-12-06 JP JP2024213907A patent/JP2025023316A/ja active Pending
-
2025
- 2025-03-19 US US19/084,586 patent/US20250243548A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20180230543A1 (en) | 2018-08-16 |
| EP2997165A4 (en) | 2017-03-08 |
| KR20210107176A (ko) | 2021-08-31 |
| EP3988673A3 (en) | 2022-08-03 |
| CN105358713B (zh) | 2020-02-28 |
| KR102295125B1 (ko) | 2021-08-31 |
| US20210371931A1 (en) | 2021-12-02 |
| EP3498867A1 (en) | 2019-06-19 |
| JP2020127437A (ja) | 2020-08-27 |
| US20250243548A1 (en) | 2025-07-31 |
| EP2997165A2 (en) | 2016-03-23 |
| JP2016526875A (ja) | 2016-09-08 |
| ES2894963T8 (es) | 2022-02-24 |
| EP3498867B1 (en) | 2021-09-29 |
| JP2022111329A (ja) | 2022-07-29 |
| JP2018148931A (ja) | 2018-09-27 |
| JP2025023316A (ja) | 2025-02-14 |
| WO2014186750A2 (en) | 2014-11-20 |
| EP3988673A2 (en) | 2022-04-27 |
| WO2014186750A3 (en) | 2015-01-08 |
| US20160090629A1 (en) | 2016-03-31 |
| US12281359B2 (en) | 2025-04-22 |
| KR20250130857A (ko) | 2025-09-02 |
| CN105358713A (zh) | 2016-02-24 |
| KR20160009582A (ko) | 2016-01-26 |
| KR20230093538A (ko) | 2023-06-27 |
| ES2894963T3 (es) | 2022-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6482533B2 (ja) | クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 | |
| Maltby et al. | Genome-wide DNA methylation changes in CD19+ B cells from relapsing-remitting multiple sclerosis patients | |
| Vanita et al. | A novel mutation in the DNA‐binding domain of MAF at 16q23. 1 associated with autosomal dominant “cerulean cataract” in an Indian family | |
| KR20130130732A (ko) | 다유전자 스코어를 이용한 진행성 노인성 황반 변성으로의 진행 예측 | |
| EP2158330A2 (en) | Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk | |
| US20160096885A1 (en) | Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis | |
| JP6689743B2 (ja) | 抑うつ症状及び不安症状の少なくとも一方を有する患者におけるバソプレッシン受容体１ｂアンタゴニストに対する治療応答を予測する方法 | |
| AU2006220604A1 (en) | Diagnostic and therapeutic target for macular degeneration | |
| CN1681941A (zh) | 基于ApoE基因型治疗痴呆的方法 | |
| Evans et al. | Novel 25 kb deletion of MERTK causes retinitis pigmentosa with severe progression | |
| Nasri et al. | A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: a case control study in an Italian population | |
| Bracken et al. | Genomewide association studies | |
| HK40072596A (en) | Variants of tnfsf15 and dcr3 associated with crohn's disease | |
| JP7090604B2 (ja) | びまん性大細胞型ｂ細胞リンパ腫の予後予測因子、及び予後予測方法 | |
| Davoudi et al. | Molecular analysis of ABCA4 gene in an Iranian cohort with Stargardt disease | |
| Davatchi et al. | HLA-B51 IN BEHCETS DISEASE | |
| JP2008534019A (ja) | ヒトニーマンピックｃ１様１遺伝子（ｎｐｃ１ｌ１）多型及びその使用方法 | |
| WO2016016824A1 (en) | Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis | |
| Hoffman | Modeling Macular Degeneration Using Quantitative Phenotypes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170425 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170425 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180402 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180629 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181023 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190117 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190130 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190212 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6482533 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |